CBD has proven effective in the management of traditional medicine-resistant pain in patients with complex and diverse diseases. It is the result of an Italian retrospective study, which was conducted by Dr. Domenico Quattrone, specialist in anesthesia and reanimation at the Pain Therapy Center of the Great Metropolitan Hospital “Bianchi Melacrino Morelli” in Reggio Calabria.

Even though the number of patients examined is small, it allows to better understand how cannabiniode, today at the center of scientific research, is safe and effective in the treatment of pain in various diseases.

10 patients, 6 male and 4 female, were retrospectively observed for 5 weeks. With an average age of 59.7 years and with proven diagnosis of chronic pain for more than 6 months, from moderate to severe pain level and upwards (NRS >6) and with proven diagnosis of neuropathic pain (Score LANSS >12/24), refractory to traditional treatments.

In the experimentation was used CBD Act Forte Oil Drops, produced by Flower Pharm and donated for compassionate use, with different dosages. The production is controlled, certified and the purified CBD is then processed in the Pharmagalenic laboratories of Dr. Marco Ternelli, with whom the company has an ongoing collaboration.


“We have started testing in several pain therapy centers around Italy, giving the product for compassionate use and testing it on different pathologies related to chronic pain such as fibromyalgia, thalamic pain or chronic pain in oncology with good results” says Antonio Cammera, biologist with 35 years of experience in the pharmaceutical field, who is the scientific responsible of Flower Pharm, “and from there we started the activity of medical information in various centers in Italy and we are finding positive results in patients with very complex clinical cases. Today there are about 150 patients in treatment using our product”.


The step forward was also made on the posology by choosing the oil after having done the necessary tests to understand what concentration of CBD there was in a single drop. “We have done appropriate research to adapt the dosage to the different clinical conditions of the patients. Of course it is all subjective, but for a 24 hour coverage we have identified a minimum average dose of 60/80 mg per day, then you can increase it keeping in mind that one drop contains 8 mg of CBD“.

On average at the beginning of therapy with CBD Act “its effectiveness is shown within 48/72 hours after administration, time necessary to stimulate receptor activity. In subsequent administrations the therapeutic effect occurs within 20 minutes after intake by sublingual route”, Cammera points out.


To understand how the study went, we spoke directly with Dr. Domenico Quattrone. “Cannabinoids and CBD in particular, are emerging in the treatment of oncohaematological patient and especially in the chronic degenerative patient, because the latter are people suffering from pain affecting them for decades and cannabinoids, because of their qualities, are establishing themselves as one of the few drugs really advisable in the medium and long term treatment. Especially THC-free formulations, which have no psychotropic effects.

And this is the case of the study in question, in which were analyzed patients representative of the most treated diseases in relation to pain. “Patients suffering from chronic oncological pain, osteomioarticular pain, of a chronic degenerative nature, and stiffness related to multiple sclerosis, to test how the CBD, in the formulation CBD Act Forte in progressive doses lowered in all patients the intensity of pain by at least 35%. In patients with chronic degenerative pain, the reduction in pain intensity was close to 60%. The patient with spasticity reported a significant improvement in quality of life with greater relaxation and ability to sleep at night.
Also, according to the doctor, “is showing a very high profile of efficacy and a very wide margin of safety because it is free of important side effects”.


On the future of the experimentation the doctor clarifies: “We are already moving forward. We have extended the indications to many other forms of pain, such as degenerative osteomioarticular pain. So, perhaps already in early 2021, the goal is to have a publication in the scientific literature of this experience”.

One thing to underline is that this type of treatment, according to the doctor, covers as an umbrella the three vulnerabilities of those who have pain related problems: “Suffering and all that it entails, the resulting disability, and especially the quality of life: I can ease the pain in the patient with large amounts of morphine, but risk depriving him/her of relational skills and autonomy”.

One final consideration: “The chronic ill population coincides with the older population, and the more time will pass, the more this population will increase. Together with the demand for analgesic therapies, for a demographic fact. The hope is that the pharmaceutical industry, the experimentation and the national health system, through their own instruments, will become more and more aware that this is a problem that could overwhelm us all in the future, generating health and social costs not to be underestimated”.

In short, all data that bodes well for the future.
Also a recent study that analyzed cannabinoids in pain management to conclude that, unlike opiates, in a long-term use, they do not change the perception of pain.

Editorial staff of Cannabisterapeutica.info